Peptide Insertion Service for Advanced AAV Vector Cell Surface Targeting

Introduction

Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector is a core capsid engineering technology. It inserts cell-specific ligand peptides into exposed variable regions of AAV capsids, enabling "ligand-receptor" specific binding to redirect vectors to target cells/tissues, boosting transduction efficiency while reducing off-target effects.

Creative Biolabs' service excels in this field: it offers tailored peptide selection (from phage libraries or custom design) and optimized insertion sites to fit diverse needs. Rigorous validation ensures capsid stability and targeting precision, delivering high-yield, functional vectors that streamline research and accelerate pre-clinical progress.

Discover How We Can Help - Request a Consultation

Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector

Core Principle

Fig.1 The basic structure and genome of AAV, an icosahedral AAV capsid composed of 60 subunits, are made up of viral proteins VP1, VP2, and VP3.¹

• Modifiability Basis of AAV Capsid: The AAV capsid (assembled from VP1/VP2/VP3) has surface Variable Regions (VRs). These regions have high amino acid plasticity without damaging capsid stability, serving as ideal sites for exogenous peptide insertion.
• Core Logic of Targeting: Receptor-specific ligand peptides (e.g., tumor-targeting RGD, nerve-targeting RVG) are genetically inserted into capsid VRs. The modified capsid binds target cell receptors via "ligand-receptor" interactions, mediating viral entry for targeted delivery.

Key Design and Implementation Strategies

Targeting peptides are derived from natural ligands like cytokine fragments, phage display peptide library screening, and computer-aided design. They need high specificity—binding only to target cell receptors, high affinity with strong binding capacity, and short sequences to avoid disrupting capsid assembly. Examples include RGD peptide targeting integrin αvβ3 on tumor cells, TAT peptide crossing the blood-brain barrier to target nerve cells, and transferrin receptor-binding peptide targeting hepatocytes or nerve cells.

Core Advantages

• Precisely Enhanced Tissue/Cell Targeting: Breaks natural AAV tropism limits (e.g., AAV9 liver accumulation), enabling muscle/CNS targeting and reducing off-target risks.
• Balancing Safety and Activity: Only modifies capsid (no genome changes), retains low immunogenicity and long-term expression; most peptides have no toxic side effects.
• High Customizability: Swappable peptides for needs like tumors or neurodegenerative diseases, enabling flexible "one backbone, multiple targets" design.

Workflow

1. Required Starting Materials: To initiate a project, clients typically provide detailed information on the following:
   • The specific cell or tissue type to be targeted.
   • The target cell-specific receptors or markers.
   • The desired AAV serotype to be used as a base.
2. Peptide Design and Selection: Our team designs high-affinity target receptor peptides, leveraging bioinformatic data and rational design for optimal binding and stability.
3. AAV Capsid Engineering: Precisely insert selected peptides into strategic AAV capsid variable regions (VRs) to alter tropism while preserving vector integrity.
4. Vector Production and Purification: Produce engineered vectors in controlled environments via advanced platforms, ensuring high titer, purity, and batch consistency.
5. Validation and Optimization: Rigorously test targeting specificity, transduction efficiency, and performance, with optional in vitro/in vivo validation for application efficacy.
6. Final Quality Control: Conduct final batch checks to meet stringent standards for purity, integrity, and functionality prior to delivery.
7. Final Deliverables: Upon project completion, you will receive:
   • A validated, ready-to-use AAV vector with enhanced targeting capabilities.
   • A comprehensive technical report detailing the design, production, and validation data.
   • Supporting documentation for the modified vector, including sequence information.
8. Estimated Timeframe: The typical timeframe for this service ranges from 8 to 14 weeks, depending on the complexity of the peptide design, the serotype used, and the scope of the validation studies requested.

What we can offer

Experience the Creative Biolabs Advantage - Get a Quote Today

Customer Reviews

"Improved In Vivo Success. Using Creative Biolabs' Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector in our research has significantly improved our ability to transduce difficult-to-reach cell types for our neuro-oncology model. The higher specificity meant we achieved a functional gene expression at a much lower dose than we initially anticipated, saving us critical time and resources."

– Time Martin, T.

"Minimizing Off-Target Effects. Using Creative Biolabs' Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector in our research has significantly reduced the off-target transduction we were seeing in our liver-directed gene therapy studies. The tailored capsid provided a cleaner safety profile in our animal models compared to traditional serotypes, which is crucial for our regulatory pathway."

– Time, Patrick S.

"Efficient, One-Stop Service. Using Creative Biolabs' Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector in our research has significantly facilitated our transition from in vitro to in vivo validation. Their comprehensive service, from design to validation, was seamless and saved our small team months of development time, allowing us to focus on data analysis instead of vector production."

– Time, Benjamin W.

FAQs

For detailed information and to discuss how our Peptide Insertion for Cell Surface Targeting of Advanced AAVs Vector Service can benefit your specific project, please reach out to our team of experts.

Contact Our Team for More Information and to Discuss Your Project

Reference

1. Chuecos, Marcel A., and William R. Lagor. "Liver directed adeno‐associated viral vectors to treat metabolic disease." Journal of inherited metabolic disease 47.1 (2024): 22-40. https://doi.org/10.1002/jimd.12637. Distributed under Open Access license CC BY 4.0, without modification.